Publications by authors named "Samuel George Bean"
Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France".
Eur J Obstet Gynecol Reprod Biol X
September 2024
Article Synopsis
- - The study compares the cost-effectiveness of the follitropin alfa biosimilar (Bemfola®) and its originator (Gonal-f®) in the French healthcare system, focusing on the cost per cumulative live-birth (CLB) based on real-world evidence rather than clinical trials.
- - A decision-tree cost-effectiveness model was used to analyze costs and cumulative live-birth rates after ovarian stimulation, including expenses from both fresh and frozen embryo transfers.
- - Results indicated that the biosimilar is more cost-effective, with a cost per CLB of €18,147 compared to €18,834 for the originator, leading to potential savings of €687 to €1,155 per